NI201100228A - Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer. - Google Patents

Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.

Info

Publication number
NI201100228A
NI201100228A NI201100228A NI201100228A NI201100228A NI 201100228 A NI201100228 A NI 201100228A NI 201100228 A NI201100228 A NI 201100228A NI 201100228 A NI201100228 A NI 201100228A NI 201100228 A NI201100228 A NI 201100228A
Authority
NI
Nicaragua
Prior art keywords
cancer
procedures
treatment
releasing factor
corticotropin releasing
Prior art date
Application number
NI201100228A
Other languages
English (en)
Inventor
Evans-Freke Stephen
Original Assignee
Stephen Evans Freke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43243708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100228(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stephen Evans Freke filed Critical Stephen Evans Freke
Publication of NI201100228A publication Critical patent/NI201100228A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en el presente documento procedimientos para tratar cáncer en un ser humano mediante la administración de CRF, opcionalmente en combinación con un segundo agente, tal como un inhibidor de angiogénesis.
NI201100228A 2009-06-24 2011-12-22 Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer. NI201100228A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22005509P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
NI201100228A true NI201100228A (es) 2012-05-23

Family

ID=43243708

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100228A NI201100228A (es) 2009-06-24 2011-12-22 Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.

Country Status (20)

Country Link
US (1) US20120183536A1 (es)
EP (1) EP2349323A2 (es)
JP (1) JP2012530740A (es)
KR (1) KR20120124353A (es)
CN (1) CN102481342A (es)
AU (1) AU2010265081A1 (es)
BR (1) BRPI1012262A2 (es)
CA (1) CA2766322A1 (es)
CL (1) CL2011003248A1 (es)
CO (1) CO6480929A2 (es)
CR (1) CR20110687A (es)
EC (1) ECSP11011550A (es)
IL (1) IL216930A0 (es)
MX (1) MX2012000203A (es)
NI (1) NI201100228A (es)
PE (1) PE20120559A1 (es)
RU (1) RU2012102259A (es)
SG (1) SG176802A1 (es)
WO (1) WO2010149357A2 (es)
ZA (1) ZA201109508B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673923B2 (en) 2011-04-29 2014-03-18 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
AU2016259007B2 (en) 2015-05-05 2022-06-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Systems and methods for providing personalized radiation therapy
EP3607952B1 (en) * 2017-04-06 2022-07-06 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or pharmaceutically acceptable salt thereof for manufacture of medicament for treatment and/or prevention of tumors
CN110384710B (zh) * 2018-04-17 2023-01-10 沈阳福洋医药科技有限公司 一种用于预防和/或治疗疼痛的药物、组合产品及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
DE3209645A1 (de) 1982-03-17 1983-09-29 Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart Vorrichtung zum regeln einer kraftfahrzeug-antriebseinheit
US4533654A (en) 1982-09-29 1985-08-06 The Salk Institute For Biological Studies Urotensin peptides
US4528189A (en) 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
EP2259793A2 (en) * 2008-04-30 2010-12-15 Neutron Row Use of corticotropin-releasing factor for the treatment of cancer
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives

Also Published As

Publication number Publication date
US20120183536A1 (en) 2012-07-19
ZA201109508B (en) 2013-05-29
CR20110687A (es) 2012-05-18
CN102481342A (zh) 2012-05-30
CL2011003248A1 (es) 2012-04-13
KR20120124353A (ko) 2012-11-13
JP2012530740A (ja) 2012-12-06
WO2010149357A3 (en) 2011-06-16
RU2012102259A (ru) 2013-07-27
PE20120559A1 (es) 2012-05-21
IL216930A0 (en) 2012-02-29
CA2766322A1 (en) 2010-12-29
SG176802A1 (en) 2012-01-30
ECSP11011550A (es) 2012-04-30
AU2010265081A1 (en) 2012-01-19
BRPI1012262A2 (pt) 2016-04-05
EP2349323A2 (en) 2011-08-03
WO2010149357A2 (en) 2010-12-29
MX2012000203A (es) 2012-04-20
CO6480929A2 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
GT201200123A (es) Nuevo uso antitumoral de cabazitaxel
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
UY36075A (es) Derivados de tubulisina
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CR20110553A (es) Terapia complementaria contra el cáncer
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
NI201100228A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.
ECSP12012132A (es) Combinación de teobromina con un descongestivo y su uso para el tratamiento de la tos
CL2015001574A1 (es) Terapia combinada para el cancer
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
AR092169A1 (es) Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla
CR20150134A (es) Arry-520 para uso en el tratamiento del cáncer en un paciente con aag baja